ThredUP Funded by New Micro VC Firm, Visterra Grabs $6M, Vivox Gets $2M From Peacock Equity, & More Boston-Area Deals News

7/14/10Follow @xconomy

(Page 2 of 2)

the two drugs get approved and hit the marketplace.

—Lexington, MA’s Highland Capital Partners joined Canadian firm BDC Venture Capital in a $12 million investment in Beyond the Rack, a Montreal-based startup. The company runs online, members-only sales on designer items. Highland has invested in other companies in the fashion and e-commerce arena, such as Gemvara, StyleFeeder, and Rent the Runway.

Visterra, the Cambridge-based developer of treatments and diagnostics for influenza and other viruses, raised $6 million in venture funding. The money comes from Flagship Ventures, Lux Capital, and Polaris Venture Partners, and will go to helping Visterra—an MIT spinout formerly named Parasol Therapeutics—expand its R&D machine to Singapore.

—Boston Millennia Partners, a venture firm focusing on investments in healthcare and life sciences companies, has raised $24.3 million from 18 investors to put toward its planned $300 million Boston Millennia Partners III LP fund, an SEC filing showed.

—Natick, MA-based voice software startup Vivox said that it has wrapped up $2 million from Peacock Equity, a fund run by GE Capital’s Media, Communications & Entertainment business and NBC Universal. Vivox, whose software is used mainly in gaming and social networking applications, will use the money to fuel growth, enter new markets, and enhance its virtual goods and audio advertising products.

Metamark Genetics, a Naples, FL-based startup that is in the process of relocating to Cambridge, said it has raised $22 million in Series B financing. The company’s diagnostics technology, which aims to identify genetic markers and other indications of tumor progression, comes from the lab of Harvard Medical School dermatology professor Lynda Chin. Metamark previously raised $4.7 million, and has declined to reveal its second round investors.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.